Alexandra Thomas

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Lajos Pusztai, Christina Yau, Denise M. Wolf et al. · Cancer Cell · 2021 · 300 citations · Full text

I-spy2 Trial, Breast Oncology, Medicine +7

Tumor mutational burden is a determinant of immune-mediated survival in breast cancer

Alexandra Thomas, Eric D. Routh, Ashok Pullikuth et al. · OncoImmunology · 2018 · 253 citations · Full text

Initial Surgery and Survival in Stage IV Breast Cancer in the United States, 1988-2011

Alexandra Thomas, Seema A. Khan, Elizabeth A. Chrischilles et al. · JAMA Surgery · 2015 · 174 citations · Full text

E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group

Roisín M. Connolly, Fengmin Zhao, Kathy D. Miller et al. · Journal of Clinical Oncology · 2021 · 112 citations · Full text

Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010–2014

Mary C. Schroeder, Priya Rastogi, Charles E. Geyer et al. · The Oncologist · 2018 · 96 citations